WHITFIELD ROY A
Known title: DirectorCIK: 0000936728
Associated companies
Transaction History
| NKTR | ▲ Buy | Grant | 2,000 | $0 | 9/23/2026 | View on chart |
| NKTR | ▼ Sell | Open Market | 30,000 | $17K | 6/14/2023 | View on chart |
| NKTR | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 | View on chart |
| NKTR | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 | View on chart |
| NKTR | ▲ Buy | Option Exercise | 40,000 | $552K | 9/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
NKTR receives mixed analyst coverage and pipeline focus
Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.
NKTR receives mixed analyst coverage and pipeline focus. Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.